What is the prescription (Rx) for Pelvic Inflammatory Disease (PID) in a hospital setting with Gonococcal (GC) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For treating Pelvic Inflammatory Disease (PID) in a hospital setting with Gonococcal (GC) infection, the recommended regimen is Gentamicin loading dose IV or IM (2 mg/kg of body weight) followed by a maintenance dose (1.5 mg/kg) every 8 hours, plus doxycycline 100 mg orally twice a day or clindamycin 450 mg orally four times a day to complete a total of 14 days of therapy. When considering the treatment of PID with GC infection, it is crucial to prioritize regimens that provide broad-spectrum coverage, including anaerobic coverage, to address the polymicrobial nature of the infection 1. The use of Gentamicin as part of the initial parenteral therapy is supported due to its efficacy against GC and other potential pathogens involved in PID 1. Following clinical improvement, the switch to oral therapy with either doxycycline or clindamycin is recommended to complete the full treatment course, with clindamycin being preferred in cases of tubo-ovarian abscess due to its enhanced anaerobic coverage 1. Alternative parenteral regimens, such as Ofloxacin or Levofloxacin with or without Metronidazole, or Ampicillin/Sulbactam plus Doxycycline, may also be considered based on specific patient needs and resistance patterns 1. However, the primary goal is to ensure adequate coverage against GC and other common PID pathogens while minimizing the risk of complications and promoting optimal patient outcomes. Key considerations in the management of PID include the severity of symptoms, presence of complications such as tubo-ovarian abscess, and the patient's ability to tolerate oral therapy, all of which may influence the choice of treatment regimen and the need for hospitalization 1.

From the FDA Drug Label

For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended. The prescription for Pelvic Inflammatory Disease (PID) in a hospital setting with Gonococcal (GC) infection is 250 mg of ceftriaxone administered intramuscularly as a single dose, and 100 mg of doxycycline administered orally twice a day for 7-14 days to cover possible co-infection with Chlamydia trachomatis 2 3.

  • Ceftriaxone dose: 250 mg IM as a single dose
  • Doxycycline dose: 100 mg PO twice a day for 7-14 days

From the Research

Prescription for Pelvic Inflammatory Disease (PID) in a Hospital Setting with Gonococcal (GC) Infection

The prescription for PID in a hospital setting with GC infection typically involves broad-spectrum antibiotic regimens.

  • The recommended treatment includes a combination of antibiotics such as ceftriaxone, doxycycline, and metronidazole 4, 5.
  • Ceftriaxone is often administered as a single dose of 250 mg intramuscularly, while doxycycline is given for 14 days 4.
  • The addition of metronidazole to ceftriaxone and doxycycline has been shown to be well-tolerated and effective in reducing endometrial anaerobes, decreasing M. genitalium, and reducing pelvic tenderness 4.
  • The treatment of PID is crucial in preventing sequelae such as tubal factor infertility and ectopic pregnancy associated with PID 6.

Antibiotic Regimens for PID

  • A systematic review and meta-analysis of randomised controlled trials found no clear evidence of a difference in the rates of cure for mild-moderate or for severe PID for various antibiotic regimens 7.
  • Commonly prescribed regimens include a combination of ceftriaxone, doxycycline, and metronidazole, which have high efficacy and safety profiles 5.
  • The choice of antibiotic regimen should be based on local and national resistance data, as well as the severity of the infection and the presence of underlying diseases 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.